Hoffmann-la Roche Inc.

Goos Van Muijen

Ulrich Weidle

Tobias Hildebrandt

Albert Zendman

A process for determining whether or not a cancer cell-containing test sample originating from or containing human cells has potential for tumor development, tumor progression or metastasis, wherein the test sample and a second sample originating from non-tumor cells obtained from the same individual or a different individual of the same species are analyzed by incubating each respective sample with a nucleic probe of sequence SEQ ID NO:1 and determining the approximate amount of hybridization of each respective sample with said probe, and comparing the approximate amount of hybridization of the test sample to an approximate amount of hybridization of said second sample to identify whether or not the test sample contains a greater amount of the specific nucleic acid or mixture of nucleic acids than does said second sample.

Process for determining the tumoricidal potential of a sample the use of a nucleic acid which is downregulated in human tumor cells

A process for the determination of CTp11 and for determining whether a tumor sample has metastatic potential is provided.

Growing community of inventors

Nijmegen, Netherlands

Goos Van Muijen